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Multidimensional instruments for determining the severity and prognosis of chronic obstructive
pulmonary disease (COPD) must be used in daily clinical practice. Objective: To develop and
validate a new COPD severity score using variables readily obtained in clinical practice and
to compare its predictive capacity with that of other multidimensional indexes.
Data collected from a prospective cohort of 611 stable COPD patients were used to derive
a clinical prediction rule that was later validated in a separate prospective cohort of 348
patients.
In the multivariate analyses, six independent predictive factors were correlated with overall
and respiratory mortality: health status, physical activity, dyspnea, airway obstruction (FEV1),
age, and hospitalizations for COPD exacerbations in the previous two years. These create the
HADO-AH score. Based on the b parameter obtained in the multivariate model, a score was as-
signed to each predictive variable. The area under the curve for 5-year mortality was 0.79 (95%
CI, 0.74e0.83) in the derivation cohort and 0.76 (95% CI, 0.71e0.81) in the validation cohort.
The HADO-AH score was a significantly better predictor of mortality than the HADO-score and
the Body-mass index, Obstruction, Dyspnea, Exercise-index were statistically significant
(p < 0.0004 and p Z 0.021, respectively), but was similar to the Age, Dyspnea, and
Obstruction-index (p Z 0.345).34 944007002.
yahoo.es (C. Esteban).
1 Published by Elsevier Ltd.
Multidimensional severity score for COPD evaluation 1663The HADO-AH score provides estimates of all-cause and respiratory mortality that are equal
to, or better than, those of other multidimensional instruments. Because it uses only easily
accessible measures, it could be useful at all levels of care.
ª 2011 Published by Elsevier Ltd.Introduction
Forced expiratory volume in 1 s (FEV1) has traditionally
been considered an essential measure for diagnosing
chronic obstructive pulmonary disease (COPD) and assess-
ing its severity. Although FEV1 still plays a key role in the
evaluation of COPD patients, as can be seen by its inclusion
in various COPD guidelines,1,2 other measures also provide
useful information in the evaluation of patients with COPD.
Combining other health measures with FEV1 provides
a more complete view of COPD patients’ clinical situation
and prognosis. This was the rationale for the development
of the Body-mass index, Obstruction, Dyspnea, and Exercise
(BODE) index,3 which has gained widespread acceptance in
the medical community. However, one of its compo-
nentsdexercise capacity, as determined by the 6-min
walking testdis difficult to apply at the primary care level.
Several research groups have attempted to improve
upon the BODE-index with multidimensional instruments
that could be used to facilitate their use and improve their
predictive capacities. These include the Health, Activity,
Dyspnea, Obstruction (HADO) score4 and the Age, Dyspnea,
Obstruction (ADO) index.5
In this study we describe the development and valida-
tion of the Health, Activity, Dyspnea, Obstruction, Age, and
Hospitalization (HADO-AH) score, which evolved from our
group’s previously developed HADO-score. We also compare
its predictive capacity to that of other multidimensional
indexes.
Methods
We recruited two independent prospective observational
cohorts of patients with stable COPD and followed each for
5-years. The derivation cohort was recruited from February
1998 to February 1999. The validation cohort was recruited
from January 2003 to January 2004. All patients were
identified from 5 outpatient clinics affiliated with
a teaching hospital.
Patients were consecutively included if they had been
diagnosed with COPD for at least six months, had been
under treatment in the hospital’s outpatient facilities for at
least six months, and had been clinically stable (no increase
in respiratory symptoms or changes in treatment) for the six
weeks prior to inclusion. Other inclusion criteria were
FEV1 < 80% of the predicted value, with a quotient FEV1/
FVC < 70% and negative bronchodilation test with a change
of FEV1 smaller than 15% and less than 200 ml of the
baseline value. Patients were not eligible for the study if
they had been diagnosed with asthma, had extensive
residual pulmonary tuberculosis, a neoplastic process, were
suffering from a psychiatric or any other problem that could
prevent effective collaboration.The variables evaluated for the development of the
HADO-AH severity index were those previously identified by
the BODE-index,3 HADO-score,4 and ADO index5: dyspnea,
FEV1 as a percentage of the expected value (FEV1%), level of
physical activity, overall health status, age, body-mass
index and 6-min walking test. We also evaluated the
number of hospitalizations for COPD exacerbations in the
previous 2 years.
The level of dyspnea was established using a scale
adapted from Fletcher6: degree 1, “dyspnea only with
intense and strenuous exercise;” degree 2, “capable of
walking at the same pace as other people my age on the
level;” degree 3, “capable of walking on the level at my
own speed without dyspnea, but incapable of walking at
the same pace as people my age;” degree 4, “dyspnea after
walking slowly for 100 m” and “dyspnea when resting or
after slight effort such as getting dressed.”
Spirometry was conducted following Spanish Respiratory
Society criteria.7 Theoretical values were those prescribed
by the European Community for Steel and Coal.8 COPD
severity was categorized following the four levels estab-
lished by the American Thoracic Society (ATS)9 based on
FEV1%. The four categories were also ordered from FEV1%
lower than 35% to FEV1% higher than 65%. The functional
parameters used were those obtained following
bronchodilation.
Patients were asked about the kinds of physical activity
(PA) they usually did. Special emphasis was placed on
walking. Level of PA was defined as the time patients spent
walking during their leisure time, and was classified into
four categories: very low (patient does not leave the house,
life is limited to the bed or armchair or to doing some
domestic chores, or leaves the house but walks less than
100 m); low (engaging in light physical activity such as
walking for less than 2 h/week), moderate (engaging in
light physical activity such as walking for 2e4 h/week), and
high (engaging in light physical activity such as walking for
more than 4 h/week). These categories are the same as
those used in previous studies.10,11
The 6-min walking test (6MWT) was conducted following
ATS guidelines.12 Two tests were conducted with a 30-min
break in between; the best result was selected.
A severe exacerbation of COPD was defined as any wors-
ening of the disease requiring hospital admission. In this
definition, admission for pneumonia, embolism, or other
causes that could complicate COPD were not included.
Body-mass index (BMI) was calculated by dividing weight
in kilograms by the square of height in meters.
We also determined the number of pack-years of ciga-
rette smoking by multiplying the number of years as
a smoker by the average number of cigarettes smoked per
day divided by 20.
Overall health was assessed by means of a single ques-
tion: “In general, how would you characterize your health?”
1664 C. Esteban et al.The 4 possible answers were “bad”, “fair”, “good” and
“very good or excellent”.
The study was approved by the research-committee of
the Hospital Galdakao-Usansolo. Patients provided
informed consent to take part in the study and all patient
personal data was kept confidential.Table 1 Characteristics of patients in the derivation and
validation cohorts.
Derivation Validation pMain outcomes
Vital status was initially determined by telephone calls
made to patients or their next of kin. All reported deaths
and dates of deaths were confirmed by reviewing medical
reports, by examination of the hospital database and public
death registries, or both. Deaths were considered
confirmed if the record matched the subject on name, sex,
and date of birth. In cases in which death occurred out of
the hospital, the researchers surveyed relatives and the
primary care doctor about the cause of death. After
analyzing all of the data, the research team made a final
determination on cause of death.n 611 348
Gender: n (%) 0.036
Male 597 (97.7) 331 (95.1)
Female 14 (2.3) 17 (4.9)
Age: mean (SD) 66.7 (8.5) 68.0 (8.49) 0.022
Mortality: n (%) 166 (27.2) 112 (32.2) 0.104
BMI: mean (SD) 27.8 (4.3) 28.2 (4.6) 0.157
Physical activity: n (%) 0.157
Very low 95 (15.6) 37 (10.6)
Low 100 (16.4) 66 (19.0)
Moderate 229 (37.5) 140 (40.2)
High 187 (30.5) 105 (30.2)
FEV1%: mean (SD) 49.7 (14.6) 55.3 (13.9) <0.001
FEV1%: n (%) <0.001
<35 101 (16.5) 29 (8.3)
(35e49) 206 (33.7) 86 (24.7)
(49e65) 192 (31.4) 138 (39.7)
>65 112 (18.3) 95 (27.3)
Level of Dyspnea: n (%) <0.001
4 28 (4.6) 31 (8.9)
3 233 (38.1) 105 (30.2)
2 306 (50.1) 159 (45.7)
1 44 (7.2) 53 (15.2)
General health: n (%) 0.257
Bad 70 (11.5) 33 (9.5)
Fair 322 (52.7) 177 (50.9)
Good 201 (32.9) 120 (34.5)
Very good-Excellent 18 (3.0) 18 (5.2)
Hospitalizations for COPD exacerbations in the
previous 2 years: n (%)
0.899
0 446 (73.0) 247 (71.0)
1 111 (18.2) 68 (19.5)
2 30 (4.9) 17 (4.9)
>2 24 (3.9) 16 (4.6)
Smoking (packs/year)
mean (SD) 47.7 (28.7) 48.5 (27.3) 0.705
20 104 (17.9) 44 (12.6) 0.190
21e59 324 (53.0) 197 (56.6)
60 183 (30.0) 107 (30.8)
SD stands for standard deviation.Statistical analysis
Descriptive analyses were conducted by calculating mean
and standard deviation for continuous variables, and
frequency and percentage for discrete variables. Compar-
isons between the derivation and the validation cohorts
were performed using Pearson’s chi-square test for discrete
variables and Student’s t-test for continuous variables. The
derivation sample was used to create a severity score.
Univariate associations between mortality and covariates
were investigated using Pearson’s chi-square test.
We fitted a multivariate logistic regression model with
all-cause death at 5-years as the dependent variable and
the original HADO variables (general health, physical
activity, dyspnea, and FEV1%) plus age and hospitalizations
for COPD exacerbations in the previous 2 years as predic-
tors.13 Generalized additive models were used to study the
functional form between covariates and mortality to find
the best categorization.14 To enhance the applicability of
the final score for clinicians, we developed a point system
from the results obtained from the multivariate logistic
model to create a crude version of the severity score, an
established approach that has been used with the Fra-
mingham risk score.15 The effect of age on the crude score
was evaluated using generalized additive models with p-
splines.14 We created a final score by adding the effect of
age for patients age 60 and older, using the method
described by Sullivan et al.15 We used calibration plots and
Hosmer and Lemeshow’s13 goodness-of-fit test to compare
the risk of death predicted by the final score with the
observed 5-year all-cause and respiratory mortality. The
predictive ability of the final score was measured by the
area under the receiver-operating curve (AUC) in the vali-
dation cohort and was compared with the same parameter
for the BODE-index, HADO-score, and ADO index in the
validation cohort. The final HADO-AH score was divided into
4 categories (mild, moderate, severe, and very severe
COPD) and the mortality rate associated with each category
was calculated.All effects were considered statistically significant at
a Z 0.05. The statistical data analysis was performed with
SAS for Windows version 9.2 (SAS Institute Inc., 1994)16 and
R (R development Core Team, 2005).17
Results
The derivation cohort included 611 patients and the vali-
dation cohort included 348 patients. The characteristics of
both cohorts, and differences between them, are described
in Table 1. The cohorts were similar in overall mortality,
BMI, level of PA, self-reported general health, hospitaliza-
tions for exacerbations of COPD in the prior 2 years, and
smoking habit (in packs/year). The validation cohort was
Table 3 Multiple logistic regression including physical
activity, FEV1, level of dyspnea, general health, and
hospitalizations for COPD exacerbations in the previous 2
years as covariates in the derivation cohort (n Z 611).
Variable Beta coefficient p Weight
RAW SCORE:
Physical activity:
Very low 1.0540 0.0021 4
Low 0.7228 0.0303 3
Medium 0.6786 0.0172 3
High 0 e 0
FEV1:
Multidimensional severity score for COPD evaluation 1665older, had slightly more women, and had higher FEV1 and
dyspnea scores.
The univariate analysis was made up of 9 measures,
including all of those used in previous COPD severity scores
(Table 2). Age, physical activity, FEV1%, categories of
dyspnea, general health, hospitalizations for exacerbations
of COPD, smoking habit, and BMI (p value Z 0.047) were
statistically significantly associated with 5-year mortality.
In the multiple logistic regression analysis in the deri-
vation sample, PA, FEV1%, dyspnea, general health, and
hospitalizations for severe exacerbations of COPD remained
significantly associated with mortality (Table 3), while BMI
and smoking habit did not. From this analysis, theTable 2 Univariate analysis of mortality and covariates in
the derivation cohort (n Z 611).
number of patients
deceased (%)
p
Gender: n (%) 0.768
Male 163 (27.3)
Female 3 (21.4)
Age: <0.001
60 13 (11.3)
61e69 57 (23.9)
70e79 87 (36.4)
80 9 (50.0)
BMI: 0.047
21 12 (44.4)
>21 154 (26.4)
Physical activity: n (%) <0.001
Very low 45 (47.4)
Low 33 (33.0)
Medium 65 (28.4)
High 23 (12.3)
FEV1%: n (%) <0.001
<35 51 (50.5)
(35e49) 60 (29.1)
(49e65) 40 (20.8)
>65 15 (13.4)
Level of dyspnea: n (%) <0.001
4 16 (57.1)
3 86 (36.9)
2 63 (20.6)
1 1 (2.3)
General health: n (%) <0.001
Bad 32 (45.7)
Fair 91 (28.3)
Good 40 (19.9)
Very good-Excellent 3 (16.7)
Hospitalizations for COPD exacerbations in the
previous 2 years: n (%)
<0.001
0 95 (21.3)
1 42 (37.8)
2 14 (46.7)
>2 15 (62.5)
Smoking (packs/year) <0.001
20 13 (12.5)
21e59 85 (26.2)
60 68 (37.2)
<35 1.5335 <0.0001 6
(35e49) 0.8846 0.0081 3
(49e65) 0.6190 0.0754 1
>65 0 e 0
Level of dyspnea:
4 2.5377 0.0245 10
3 2.1592 0.0390 8
2 1.8172 0.0802 6
1 0 e 0
General health:
Bad 0.4482 0.1356 1
Other 0 0 0
Hospitalizations for COPD exacerbations in the previous 2
years:
>2 1.2661 0.0067 5
2 0.9830 0.0180 4
1 0.5235 0.0332 2
0 0 e 0
SCORE ADJUSTED BY AGE:
Age (>60 years)a 0.0727 0.0004 0.30/year
a This corresponds to the beta coefficient of the logistic model
including mortality as response variable and the raw score and
age as explanatory variables.categories for each variable were weighted according to
their b coefficients. The effect of age on the crude score
was evaluated using generalized additive models with
p-splines (Fig. 1). They showed that the functional form of
the relationship was not lineardthe crude score retained
the effect of age for patients under age 60, but was
constant for patients age 60 and above. Therefore, the
effect of age was added to the raw score for patients aged
60 and above, with a weight given by the b coefficient of
age in the logistic model including mortality as the response
variable, and the raw score and age as explanatory vari-
ables, to create a final score adjusted by age (Table 3). This
is the HADO-AH score.
The HADO-AH score was applied to the derivation and
validation cohorts. For 5-year all-cause mortality, the AUCs
were 0.79 (95% CI, 0.74e0.83) in the derivation cohort and
0.76 (95% CI, 0.71e0.81) in the validation cohort. For 5-year
respiratory mortality, the AUCs were 0.81 (95% CI,
0.76e0.85) in the derivation cohort and 0.78 (95% CI,
0.72e0.84) in the validation cohort. The HADO-AH score
provided a good match between 5-year predicted and
observed mortality (Fig. 2). The value of the
Figure 1 Non-linear relation using p-splines between age
and the raw score created using general health, FEV1, level of
dyspnea, physical activity, and hospitalizations for COPD
exacerbations in the previous 2 years.
1666 C. Esteban et al.HosmereLemeshow statistic was 11.07 in the derivation
sample and 6.49 in the validation sample (p Z 0.20 and
pZ 0.59 with 8 degrees of freedom, respectively).
From the HADO-AH score, we created 4 severity cate-
gories, as shown in Table 4: mild COPD, 10 points;
moderate COPD, 10 to <15 points; severe COPD, 15 to
<20 points; and very severe COPD, 20 points. Five-year
mortality rates increased from mild to very severe COPD
categories. Statistically significant differences were
observed across the categories in the derivation sample for
all-cause mortality while there were no differences
between those in the moderate versus mild categories in
the validation sample. For respiratory mortality differences
across the categories were also statistically significant
except for the moderate versus mild categories in both
samples. The AUCs for 5-year all-cause mortality were 0.75
(95% CI, 0.71e0.79) in the derivation cohort and 0.74 (95%
CI, 0.68e0.79) in the validation cohort; for 5-year respira-
tory mortality, the AUCs were 0.79 (95% CI, 0.74e0.83) in
the derivation cohort and 0.76 (95% CI, 0.71e0.83) in the
validation cohort.
Finally, we compared the predictive capacity of the
HADO-AH score with three previously developed COPD0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
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Figure 2 Calibration plot of the HADO-AH score adjusseverity scores: the BODE-index, HADO-score, and ADO
index (Fig. 3). The HADO-AH had the highest AUC of the
four. The HADO-AH score was statistically significantly
better than the BODE-index (pZ 0.02) and the HADO-score
(p Z 0.0004), but was not significantly different from the
ADO index (pZ 0.34). The predictive capacity of the HADO-
AH score at 3 years was very similar than that obtained at 5-
years (Fig. 3).
Discussion
A simple scoring system consisting of 6 variables easily
obtained in daily practice provides important prognostic
information about 5-year all-cause and respiratory
mortality for patients with COPD. This new score, the
HADO-AH score, performs as well as, or better than, the
landmark BODE-index and other instruments that have
evolved from it.
The HADO-AH score is based on the HADO-score devel-
oped by our group.4 Adding 2 variables to the HADO-
scoredage5 and hospitalizations for severe exacerbations
of COPD18 in the previous 2 yearsdimproved its prognostic
ability. One of our goals in creating this new score was to
use variables familiar to clinicians that are easily obtained
in daily clinical practice. The BODE-index, for example,
includes exercise capacity as measured by the 6-min
walking test, which some clinics are not set up to
perform. We also changed the direction of the scoring
system (in the HADO-AH, the higher the score, the worse
the prognosis) to make it more directly comparable to other
multidimensional scales of COPD severity.
The prognostic capacities of two of the variables used in
the HADO-AH, FEV1 and dyspnea, have already been
demonstrated in previous studies.19e22 Whether dyspnea is
a more important prognostic factor than FEV1 is unknown,
with conflicting findings in this area.21,22 These differences
may be related to the fact that dyspnea is not associated
solely with respiratory disease, but is also frequently
associated with heart failure a conditions that may
accompany COPD.23
The HADO-AH score includes two other variables that
have also been used in the development of some multidi-
mensional scales. Severe exacerbations of COPD requiring0.1 0.2 0.3 0.4 0.5 0.6 0.7
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ted by age in the derivation and validation cohorts.
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Figure 3 Prediction ability of the HADO-AH score compared
to the BODE-index, HADO-score, and ADO index in the valida-
tion cohort (n Z 348). AUC and the 95% confidence interval is
shown for each index. a) 5-year all-cause mortality risk: The
HADO-AH score was significantly different from the BODE-index
(pZ 0.02) and HADO-score (pZ 0.0004) but was not different
from the ADO index (p Z 0.34). b) 3-year all-cause mortality
risk: The HADO-AH score was significantly different from the
HADO-score (pZ 0.03) but was not different from BODE-index
(p Z 0.31) and the ADO index (p Z 0.13).
Multidimensional severity score for COPD evaluation 1667hospitalization have been shown to have an independent
association with mortality.18 However, when Soler et al.24
added exacerbations requiring hospitalization or an
assessment in the emergency department to the BODE-
index, the new e-BODE index was not significantly better
(C statistic 0.77 [95% CI, 0.67e0.86]) than the original
BODE-index (C statistic 0.75 [95% CI, 0.66e0.84]). Why
1668 C. Esteban et al.would the addition of severe exacerbations of COPD to the
BODE-index fail to improve predictive ability, even though
both severe exacerbations and the BODE-index have proved
to be independent prognostic factors? The authors suggest
the limited sample size as one reason. It could also be
possible that the impact of exacerbations is somehow
already registered in other variables comprising the BODE-
index, such as the capacity for exercise or FEV1. In fact,
previous hospitalization for COPD has been associated with
lower PA.25 When Soler et al.24 replaced the 6MWT with
severe exacerbations in the BODEx index, it had a similar
prognostic capacity (C statistic 0.74 [95% CI, 0.65e0.83]) as
the original BODE-index. We should also mention that in the
Soler study, the cut-points used to establish exacerbation
categories were determined following objective criteria.
Besides, these cut-off points were based on a study18 in
which assessment in the emergency department were
excluded, since it was shown they did not have an impact
on mortality. This may have influenced on the results. In
our study the classification of exacerbations was different
as the fact of adding one only exacerbation already
increased the mortality risk and consequently the impor-
tance given to each category was also different.
Age has long been acknowledged as a prognostic factor
for COPD-associated mortality,19e22,26 even though it was
not included in the BODE-index. Publication of the ADO
index5 revived interest in it. In our study, the contribution
of age to 5-year mortality was already included in the
score up to the age of 60. After that, however, age begins
to exert its own independent effect. However, the weight
given to age in the HADO-AH score is noticeably lower than
in the ADO index. Although age is an influential factor in
the prognosis of any disease,27 some experts have argued
against its inclusion in these types of instruments since it
not a modifiable factor.28 In addition, aging is not
a uniform process, depending largely upon genetic, life-
style, and environmental factors. In other words, chrono-
logical age is not necessarily the same as biological age,
with the latter having a greater influence on mortality.
Unlike chronological age, biological age is a potentially
modifiable risk factor. How to measure biological age-
dimmunosenescence, inflammatory responses, oxidative
stress, telomere length in peripheral blood leukocytes29 or
dysfunctional telomere markers30dhas not yet been
determined.
The HADO-AH score includes 2 variablesdthe patient’s
perception of his or her health and PAdthat are not found
in other multidimensional measures of COPD severity.
Perception of health has been shown to be a good predictor
of general mortality in the general population, and the
single health-related question we used stratified patients
with different mortality risks.31 Meta-analysis suggests
a strong association between self-perceived health status
and mortality, even after adjustment for key covariates
such as functional status, depression, and co-morbidity,
with individuals reporting “poor” health having higher
mortality than their counterparts reporting “excellent”
health (OR, 1.74; 95% CI, 1.51e2.02).32
In a population-based cohort among patients with COPD,
Garcia-Aymerich et al. showed that even slight amounts of
PA (equivalent to walking or bicycling for 2 h per week)
decreased by 30%e40% the risk of hospitalization due toCOPD and the risk of respiratory mortality.10 Replacing PA
with the 6MWT in the validation cohort in our study did not
change the model’s predictive capacity (AUC 0.75 [95% CI,
0.69e0.81]). Yet in the multivariate analysis, both variables
demonstrated an independent relationship with mortality
(data not shown), which could justify the replacement of
6MWT with patient-reported PA, thus making the instru-
ment easier for clinicians to use.
BMI did not turn out to be a significant predictor of 5-
year mortality in the HADO-AH. This is in contrast to other
studies of COPD patients,3 where it was a useful predictor
of mortality.
Surprisingly, in our cohort the BODE-index, applying the
cut-off points established by the original BODE authors,
showed a similar predictive capacity (AUC 0.72) to the one
described in original BODE cohort (AUC 0.74), which has
also been proved in other study (AUC 0.75)24 and signifi-
cantly higher than the one referred to by Puhan et al. which
ranged from (AUC 0.67) in the their Swiss cohort and (AUC
0.62) in the their Spanish cohort.5 We were surprised that
the ADO index score for our derivation and validation
cohorts (AUC 0.74) was so much higher than that of the
original ADO index (AUC 0.63). It is not clear why this
difference exists. It is possible that the treatment of
missing values in the original study and the use, in the Swiss
cohort, of the dyspnea domain of the Chronic Respiratory
Questionnaire, which is applied from a series of activities
chosen by each patient in order to establish the degree of
dyspnea, could have led to a low AUC in the original ADO
study.
Compared with the ADO Index, our score include similar
variables but, in our case, age is taken not linearly but from
60 years when it seems to be related to mortality. We add
three easily obtainable variables in primary care settings to
better discriminate among patients. Finally, though the
predictive ability of both indexes in our sample was not
statistically significant the AUC of the ADO index in the
original article was far lower than our index.
Our study has several strong points: We used 2 inde-
pendent cohorts, one for derivation and one for validation
that included a large number of patients. The 5-year
follow-up period for both cohorts was significantly longer
than the 3-year follow-up in other previous multidimen-
sional scales. The AUCs we obtained at 3 years for all-cause
mortality (AUC, 0.78; 95% CI, 0.72e0.84) and respiratory
mortality (AUC, 0.76; 95% CI, 0.70e0.84) are similar to
those we determined for 5-year all-cause and respiratory
mortality, reflecting the stability of the HADO-AH score
over time. We applied a weighting system to the variables
that improves the prognostic capacity of the HADO-AH
score over the HADO-score. Appropriately weighting the
contribution of each variable is such an important
contributor to the overall score that the BODE-index was
criticized for not including this statistical methodology.5
The HADO-AH score is valid as a prediction tool for all-
cause and for respiratory mortality, which has not always
been assessed in other indexes. When compared with other
multidimensional systems, the HADO-AH score (AUC, 0.76;
95% CI, 0.71e0.82) is somewhat better than the BODE-index
for predicting all-cause mortality (AUC, 0.72; 95% CI,
0.66e0.78; p Z 0.02) and equal to the ADO index (AUC,
0.74; 95% CI, 0.69e0.80; p Z 0.35).
Multidimensional severity score for COPD evaluation 1669Limitations of our study must also be noted. The HADO-
AH was derived from and validated in patients recruited
from a single hospital, which could limit the generaliz-
ability of the results. Both cohorts were predominately
male, reflecting the history of smoking patterns in northern
Spain, which was traditionally restricted to men.33 Our
score includes some objective variables like the FEV1,
number of previous hospitalizations, or age and other more
subjective like dyspnea, self-reported physical activity, and
health status but the validity of these has been checked in
different settings and languages.10,11,31,32,34 It is possible
that patterns of COPD changed between the time the
derivation cohort was recruited (1998e1999) and the time
the validation cohort was recruited (2003e2004), as sug-
gested by the increase in the number of women in the
validation cohort. The predictive capacity of the HADO-AH
score is clearly capable of improvement. This, however,
would likely require the use of variables such as pulmonary
hypertension or muscle strength that are not readily
accessible to clinicians, which would restrict its use. One
possibility would be to create a more complex score for
more severely ill patients that could be applied at more
specialized levels of care.
The HADO-AH score represents another step in the
evolution of instruments for evaluating the severity and
prognosis of COPD. Using 6 measures readily available in
clinical practice, it predicts 5-year mortality as well as, or
better than, earlier instruments that require harder-to-
come-by data. Although the HADO-AH score could be
further improved, and must be validated in other pop-
ulations, it represents a potentially useful tool for clinical
decision making at all levels of care.Acknowledgments
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